Bristol Myer Revenue vs. Cash Flow from Operations

BMYMP
 Stock
  

USD 1,200  10.00  0.84%   

For Bristol Myer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bristol Myer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bristol Myer Squi utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bristol Myer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bristol Myer Squi over time as well as its relative position and ranking within its peers. Continue to Trending Equities.
  
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bristol Myer Squi Cash Flow from Operations vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myer's current stock value. Our valuation model uses many indicators to compare Bristol Myer value to that of its competitors to determine the firm's financial worth.
Bristol Myer Squi is the top company in revenue category among related companies. It is number one stock in cash flow from operations category among related companies making about  0.23  of Cash Flow from Operations per Revenue. The ratio of Revenue to Cash Flow from Operations for Bristol Myer Squi is roughly  4.27 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myer by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myer's OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myer's earnings, one of the primary drivers of an investment's value.

Bristol Revenue vs. Competition

Bristol Myer Squi is the top company in revenue category among related companies. Market size based on revenue of Drug Manufacturers - Major industry is currently estimated at about 1.02 Trillion. Bristol Myer holds roughly 21.6 Billion in revenue claiming about 2.11% of equities under Drug Manufacturers - Major industry.

Bristol Cash Flow from Operations vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Bristol Myer 
Revenue 
 = 
Money Received 
Discounts and Returns 
21.6 B
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Bristol Myer 
Operating Cash Flow 
 = 
EBITDA 
-  
Taxes 
5.06 B
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Bristol Cash Flow from Operations Comparison

Bristol Myer is currently under evaluation in cash flow from operations category among related companies.

Bristol Myer Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bristol Myer, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bristol Myer will eventually generate negative long term returns. The profitability progress is the general direction of Bristol Myer's change in net profit over the period of time. It can combine multiple indicators of Bristol Myer, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.

Bristol Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bristol Myer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bristol Myer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bristol Myer's important profitability drivers and their relationship over time.

Use Bristol Myer in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myer will appreciate offsetting losses from the drop in the long position's value.

Bristol Myer Pair Trading

Bristol Myer Squi Pair Trading Analysis

The ability to find closely correlated positions to Bristol Myer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myer Squi to buy it.
The correlation of Bristol Myer is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myer Squi moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bristol Myer position

In addition to having Bristol Myer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Large Blend Thematic Idea Now

Large Blend
Large Blend Theme
Fund or Etfs that invest in stocks of large organizations that have characteristics of both growth and value companies. The Large Blend theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Blend Theme or any other thematic opportunities.
View All  Next Launch
Continue to Trending Equities. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
To fully project Bristol Myer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bristol Myer Squi at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bristol Myer's income statement, its balance sheet, and the statement of cash flows.
Potential Bristol Myer investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bristol Myer investors may work on each financial statement separately, they are all related. The changes in Bristol Myer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.